EUVIMEDEUVIMED entdecken
Crossref

Postoperative molecular residual disease status refines recurrence risk stratification beyond pathologic response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma

Zhichao Liu, Yang Yang, Boyao Yu, Yuxin Yang, Chang Yuan, Chunji Chen, Xinyu Yang, Shaoyuan Zhang, Chunguang Li, Yinkai Chao, Simon Law, Zhigang Li

The Journal of Thoracic and Cardiovascular Surgery · 2026-09 · 172 (3) · 753-766.e8

DOI: 10.1016/j.jtcvs.2026.04.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2026-09. Verfasst von Zhichao Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: liuzc…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Neoplasms, Neoplasm Recurrence, Local, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Hospital Development Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Accurate postoperative recurrence-risk stratification is essential for adjuvant treatment decisions in esophageal cancer after neoadjuvant chemoradiotherapy. Pathologic complete response is widely used for risk assessment but shows limited discrimination. This study evaluated whether integrating postoperative molecular residual disease with pathologic response improves recurrence prediction. METHODS: This was a post hoc analysis of the preSINO trial. Patients with locally advanced esophageal squamous cell carcinoma who underwent neoadjuvant chemoradiotherapy followed by esophagectomy (2019-2023) and had molecular residual disease assessment were included. Molecular residual disease status was determined 3 to 4 weeks postsurgery using a tumor-informed personalized circulating tumor DNA assay. Recurrence-free survival and recurrence patterns were analyzed. RESULTS: Ninety-three patients were included, of whom 30 experienced recurrences during a median follow-up of 36.5 months. Most recurrences (73.3%) occurred within the first year postsurgery. A trend toward a lower 1-year recurrence rate was observed in patients with a pathologic complete response (13.5%) compared with patients without a pathologic complete response (30.4%) (P = .061). Molecular residual disease status significantly stratified recurrence-free survival and early recurrence risk, with 1-year recurrence rates of 6.1% versus 66.7% for molecular residual disease-negative versus molecular residual disease-positive groups (P < .001). Multivariable Cox-regression analysis demonstrated molecular residual disease positivity (hazard ratio, 13.62; P < .001) as an independent predictor of recurrence-free survival, whereas pathologic response was not. A classification combining pathologic complete response/non-pathologic complete response and molecular residual disease status identified 4 distinct recurrence risk subgroups: The 1-year recurrence rates were 3.7% of pathologic complete response and molecular residual disease negative, 7.7% of non-pathologic complete response and molecular residual disease negative, 40% of pathologic complete response and molecular residual disease positive, and 82.4% of non-pathologic complete response and molecular residual disease positive (P < .001), with distant recurrence predominating in molecular residual disease-positive groups. CONCLUSIONS: Integrating postoperative molecular residual disease with pathologic response improves recurrence risk stratification that may facilitate adjuvant therapy decisions but warrants prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyEsophageal NeoplasmsNeoplasm Recurrence, LocalEsophageal Squamous Cell CarcinomaEsophagectomyChemoradiotherapy, AdjuvantHumansNeoplasm, ResidualMaleRisk AssessmentFemaleMiddle AgedPathologic Complete ResponseAgedRisk Factors

Stichwörter der Autor:innen

esophageal squamous cell carcinomamolecular residual diseaseneoadjuvant chemoradiotherapypathologic complete responserecurrence

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: liuzc1995@163.com.
  • Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Division of Thoracic Surgery, Chang Gung Memorial Hospital-Linkou, Chang Gung University, Taiwa…
  • Division of Thoracic Surgery, Chang Gung Memorial Hospital-Linkou, Chang Gung University, Taiwan, China.
  • Department of Surgery, LKS Faculty of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
  • Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: zhigang.li@shsmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Shanghai Hospital Development Center

Zitieren

APA

Liu, Z., Yang, Y., Yu, B., Yang, Y., Yuan, C., Chen, C., Yang, X., Zhang, S., Li, C., Chao, Y., Law, S., & Li, Z. (2026). Postoperative molecular residual disease status refines recurrence risk stratification beyond pathologic response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. The Journal of Thoracic and Cardiovascular Surgery, 172(3), 753-766.e8. https://doi.org/10.1016/j.jtcvs.2026.04.014

Vancouver

Liu Z, Yang Y, Yu B, Yang Y, Yuan C, Chen C, et al. Postoperative molecular residual disease status refines recurrence risk stratification beyond pathologic response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. The Journal of Thoracic and Cardiovascular Surgery. 2026;172(3):753-766.e8. doi:10.1016/j.jtcvs.2026.04.014

BibTeX
@article{Liu2026,
  author = {Liu, Zhichao and Yang, Yang and Yu, Boyao and Yang, Yuxin and Yuan, Chang and Chen, Chunji and Yang, Xinyu and Zhang, Shaoyuan and Li, Chunguang and Chao, Yinkai and Law, Simon and Li, Zhigang},
  title = {Postoperative molecular residual disease status refines recurrence risk stratification beyond pathologic response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2026},
  volume = {172},
  number = {3},
  pages = {753--766.e8},
  doi = {10.1016/j.jtcvs.2026.04.014}
}
Kostenlos starten →